Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and CRC. In addition, its preclinical stage products include IBB0979, an immunocytokine for solid tumors; IBC0966, a clinical stage anti-PD-L1 antibody-signal regulatory protein bifunctional fusion protein for tumor specific immune responses; IBD0333 for solid tumor; IAN0982 for advanced solid tumors; ISH0988, an internally developed bifunctional antibody fusion protein for the treatment of systemic lupus erythematosus; and ISH0613, an internally developed bifunctional anti-inflammatory bispecific antibody for the treatment of inflammatory bowel disease. The company was founded in 2018 and is headquartered in Huzhou, China. Sunho Biologics, Inc. is a subsidiary of Sunho Wisdom Investments Limited.